SLC5A2 and type 2 diabetes mellitus: However, the proportion of participants with concomitant HF was small in these CVOTs, and there is limited evidence as to whether SGLT2 inhibitors have different effects on HF-related parameters in patients with T2D and concomitant HF, according to their use of glucose-lowering agents.